Two studies in the New England Journal of Medicine this week look at adding bevacizumab, better known as Avastin, to ovarian cancer therapies. Bevacizumab is used to treat other cancers, including colorectal and lung. In the first article, Fox Chase Cancer Center's Robert Burger and his colleagues found that the addition of bevacizumab to chemotherapy led to an increase in progression-free survival.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.